secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-08-05T20:09:28+00:00
Accession:  0001517022-26-000050
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q2 2026: Vafseo revenue $21.3M (+34% QoQ); net loss $8.9M
----------------------------------------------------------------

- Vafseo net product revenue $21.3M in Q2 2026, up 34% from Q1; over 10,500 patients on therapy.
- Total revenue $49.1M, down 20% YoY due to Auryxia generic competition ($25.5M vs $47.2M).
- Net loss of $8.9M vs net income of $0.2M in Q2 2025; includes $1.9M restructuring charge.
- Cash $155.5M as of June 30; company expects to fund operations for at least two years.
- Initiated Phase 2 basket trial of ebribafusp for rare kidney diseases; initial data expected 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/0001517022-26-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/akba-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer